Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 2, 1998, Pages 120-128

  Hartmann, Katrin ^a,f   Kuffer, Manuela ^a   Balzarini, Jan ^b   Naesens, Lieve ^b   Goldberg, Michel ^a   Erfle, Volker ^c   Goebel, Frank Detlef ^a   De Clercq, Erik ^b   Jindrich, Jindrich ^d   Holy, Antonin ^d   Bischofberger, Norbert ^e   Kraft, Wilfried ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^e GILEAD SCIENCES   (United States)

^f I Medizinische Tierklinik   (Germany)

Author keywords

Acyclic nucleoside phosphonates; AIDS; Chemotherapy; FIV; FPMPA; PMEA

Indexed keywords

9 (3 FLUORO 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ADEFOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CAT; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FELINE IMMUNODEFICIENCY VIRUS; HELPER CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS INHIBITION;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; CATS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; KARNOFSKY PERFORMANCE STATUS; MALE; PHOSPHONIC ACIDS; PLACEBOS; REFERENCE STANDARDS; STOMATITIS; VIRAL LOAD;

EID: 11344272219     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802010-00004     Document Type: Article

References (42)

1. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 1995;8:200-39.
2. De Clercq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem 1995;38:2491-517.
3. De Clercq E. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Rev Med Virol 1996;6:97-117.
4. Pedersen NC, Ho EM, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987;235:790-3.
5. Pedersen NC, Yamamoto JK, Ishida T, Hansen H. Feline immunodeficiency virus infection. Vet Immunol Immunopathol 1989;21: 111-29.
6. Olmsted RA, Barnes AK, Yamamoto JK, Hirsch VM, Purcell RH, Johnson PR. Molecular cloning of feline immunodeficiency virus. Proc Natl Acad Sci USA 1989;86:2448-52.
7. Olmsted RA, Hirsch VM, Purcell RH, Johnson PR. Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc Natl Acad Sci USA 1989;86:8088-92.
8. Talbott RL, Sparger EE, Lovelace KM, Fitch WM, Pedersen NC, Luciw PA, Elder JH. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA 1989;86:5743-7.
9. Harbour DA, Williams PD, Gruffydd-Jones TJ, Burbridge J, Pearson GR. Isolation of a T-lymphotropic lentivirus from a persistently leucopenic domestic cat. Vet Rec 1988;122:84-6.
10. Ishida T, Washizu T, Toriyabe K, Motoyoshi S, Tomoda I, Pedersen NC. Feline immunodeficiency virus infection in cats of Japan. J Am Vet Med Assoc 1989;194:221-5.
11. Hartmann K, Hinze K. Epidemiologic und Klinik der FIV-Infektion in Bayern. Tierärztl Prax 1991;19:545-51.
12. North TW, North GT, Pedersen NC. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother 1989;33:915-19.
13. Egberink H, Borst M, Niphuis H, et al. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci USA 1990;87:3087-91.
14. Hartmann K, Donath A, Beer B, et al. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 1992;35:167-75.
15. Vahlenkamp TW, De Ronde A, Balzarini J, et al. (R)-9-(2-Phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrob Agents Chemother 1995;39:746-9.
16. De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323:464-7.
17. De Clercq E. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem Pharmacol 1991;42:963-72.
18. Balzarini J, Naesens L, Herdewijn P, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989;86:332-6.
19. Balzarini J, Naesens L, Slachmuylders J, et al. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 1991;5:21-8.
20. Tsai C-C, Follis KE, Sabo A, Grant R, Bischofberger N. Efficacy of 9-(2-phosphony)methoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis 1995;171:1338-43.
21. Naesens L, Balzarini J, Bischofberger N, De Clercq E. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)-adenine. Antimicrob Agents Chemother 1996;40:22-8.
22. Balzarini J, Holy A, Jindrich J, Naesens L, Snoeck R, Schols D, De Clercq E. Differential antiherpesvirus antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993;37:332-8.
23. Tsai C-C, Follis KE, Beck TW, Sabo A, Grant RF, Bischofberger N, Benveniste RE. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl)adenine (PMPA). Science 1995;270:1197-9.
24. Bischofberger N. Lecture at the Ninth International Conference on Antiviral Research, Urabandai, Fukushima, Japan, May 19-24, 1996.
25. Holý A, Rosenberg I, Dvoráková H. Synthesis of N-(2-phosphonylmethoxyethyl) derivatives of heterocyclic bases. Collect Czech Chem Commun 1989;54:2190-210.
26. Jindrich J, Holý A, Dvoráková H. Synthesis of N-(3-fluoro-2-phosphonomethoxypropyl) (FPMP) derivatives of heterocyclic bases. Collect Czech Chem Commun 1993;58:1645-67.
27. Balzarini J, Holý A, Jindrich J, et al. 9-[(RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc Natl Acad Sci USA 1991;88:4961-5.
28. Hartmann K, Balzarini J, Higgins J, De Clercq E, Pedersen NC. In vitro activity of acyclic nucleoside phosphonate derivatives against feline immunodeficiency virus in Crandell feline kidney cells and feline peripheral blood lymphocytes. Antiviral Chem Chemother 1994;5:13-19.
29. Naesens L, Balzarini J, De Clercq E. Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. Clin Chem 1992;38: 480-5.
30. Hartmann K, Kuffer M, Egberink H, Lutz H, Kraft W. Diagnostik der FIV-Infektion. Tierärztl Prax 1994;22:268-72.
31. Karnofsky DA, Abelmann WH, Graver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948:634-56.
32. Hartmann K. Referenzbereiche in der Labordiagnostik der Katze. Tierärztl Prax 1989;5:58-62.
33. Fuchs D, Unterweger B, Hausen A, et al. Anti-HIV-1 antibodies, anti-HTLV-I antibodies and neopterin levels in parenteral drug addicts in the Austrian Tyrol. J Acquir Immune Defic Syndr Hum Retrovirol 1988;1:65-6.
34. Reddy MM, McKinley GF, Grieco MH. Evaluation of HIV p24 antigen, beta2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2′,3′-dideoxyinosine (ddI). J Clin Lab Anal 1991;5:396-8.
35. Goldberg M, Gassner F, Singer LJ, Merkenschlager M. Pteridinkonzentrationen in Harn und Organgeweben von Hund und Katze bei verschiedenen Neoplasien und Virusinfektionen. Tierärztl Prax 1989; Suppl 5:37-41.
36. Balzarini J, Naesens L, De Clercq E. Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. Int J Cancer 1990;46:337-40.
37. Naesens L, Balzarini J, De Clercq E. Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res 1991;16:53-64.
38. Hagberg L, Norkraus G, Andersson M, Wachter H, Fuchs D. Cerebrospinal fluid neopterin and β2-microglobulin levels in neurologically asymptomatic HIV-infected patients before and after zidovudine treatment. Infection 1992;20:313-15.
39. Caliò R, Villani N, Balestra E, et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994;23:77-89.
40. Huber C, Batchelor JR, Fuchs D, et al. Immune responseassociated production of neopterin. J Exp Med 1984;160:310-16.
41. Bitterlich G, Szabo G, Werner ER, et al. Selective induction of mononuclear phagocytes to produce neopterin by interferons. Immunobiology 1988;176:228-35.
42. Barak M, Gruener N. Neopterin augmentation of tumor necrosis factor production. Immunol Lett 1991;30:101-6.